Chitogen Inc

Chitogen Inc manufactures next-generation hemostatic products utilizing proprietary chitosan fiber technology to accelerate natural blood clot formation. The company's flagship product, the SoftSeal-STF (Surface Treated Fiber) Hemostatic Pad, is FDA-approved and designed for rapid hemostasis with improved patient comfort and reduced compression time. Chitogen products serve surgical, cardiovascular catheterization, and dialysis environments, offering patented technology that demonstrates proven improvement in time to hemostasis. The product line combines clinical efficacy with superior staff and patient satisfaction, addressing critical bleeding control needs across multiple clinical settings. The company emphasizes safety, speed, and ease of use in perioperative and interventional care applications.